Targovax’s ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival
· Median overall survival (mOS) for first-line treatment with ONCOS-102 plus chemotherapy will be between 21.9 and 25.0 months, compared with mOS of 13.5 months in the chemotherapy-only control group · Broad and powerful immune activation pattern observed in patients treated with ONCOS-102, clearly associated with both tumor responses and survival outcomes Oslo, Norway, 10 June 2021 - Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces mOS between 21.9 and 25.0 months from the randomized